LONDON, United Kingdom, July 6, 2026
AMO Pharma Limited has announced a significant regulatory milestone for its investigational therapy AMO-02 (oral tideglusib) after receiving aligned scientific advice from the U.S. Food and Drug Administration (FDA), the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada regarding the design of its planned registrational clinical study for congenital myotonic dystrophy type 1 (cDM1). The coordinated feedback provides a clear regulatory pathway for evaluating the safety and efficacy of AMO-02, an investigational oral therapy being developed for one of the most severe inherited neuromuscular disorders affecting children. Based on recommendations from the three regulatory agencies, the upcoming registrational trial will use hospitalization as the primary efficacy endpoint, supported by multiple functional assessments as secondary outcome measures. The milestone represents an important step toward advancing a potential treatment for cDM1, a rare genetic disease that currently has no approved disease-modifying therapies and remains associated with substantial medical complications, lifelong disability, and significant caregiver burden.
Global Regulatory Alignment Strengthens Registrational Study Design
The scientific advice received from the FDA, MHRA, and Health Canada followed a series of regulatory meetings conducted over the past six months and provides AMO Pharma with a harmonized framework for its pivotal clinical development program. The registrational study will evaluate whether AMO-02 can reduce hospitalizations, a clinically meaningful endpoint that reflects the severe and multisystem complications associated with congenital myotonic dystrophy type 1. Individuals living with cDM1 frequently require repeated hospital admissions due to respiratory complications, cardiac abnormalities, muscle weakness, developmental challenges, and other serious medical conditions.
In addition to hospitalization as the primary endpoint, the study will include multiple functional outcome measures to assess disease progression and capture improvements in physical function, neurological development, and other clinically important aspects of the disorder. AMO Pharma also plans to engage patients and caregivers through community surveys to better understand the real-world burden of symptoms and hospitalization, ensuring that future clinical development remains focused on outcomes most meaningful to affected families.
AMO-02 Targets a Critical Unmet Need in Rare Neuromuscular Disease
Advertisement
Congenital myotonic dystrophy type 1 is a rare inherited neuromuscular disorder that begins at birth and affects multiple organ systems throughout life. Children with cDM1 often experience severe muscle weakness, respiratory insufficiency, developmental delay, learning disabilities, cardiac complications, and prolonged hospitalizations that significantly impact quality of life. Despite advances in supportive care, there are currently no approved therapies specifically designed to modify the progression of cDM1, leaving patients and families with limited treatment options. AMO-02 (oral tideglusib) is an investigational small-molecule therapy that is being evaluated for its potential to address the underlying biological mechanisms contributing to disease progression.
Company leadership noted that the regulatory guidance provides a clear path toward initiating a registrational trial while supporting the development of clinically meaningful endpoints capable of demonstrating therapeutic benefit in this underserved patient population. The company expects to provide an update on trial initiation during the third quarter of 2026.
Rare Disease Development Advances Through International Collaboration
The latest regulatory milestone reinforces AMO Pharma’s commitment to developing innovative therapies for rare genetic disorders with significant unmet medical needs. Beyond its cDM1 program, the company is also investigating AMO-02 as a potential treatment for Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), further expanding its rare disease pipeline. The alignment achieved among three major regulatory authorities highlights the increasing importance of international collaboration in accelerating development programs for rare diseases, where limited patient populations require efficient and globally coordinated clinical strategies.
By incorporating patient-focused outcome measures alongside regulatory guidance, AMO Pharma aims to generate robust clinical evidence capable of supporting future regulatory submissions while addressing meaningful health outcomes for patients and caregivers. As global interest in rare disease therapeutics continues to grow, the planned registrational study represents an important milestone in advancing precision medicine for congenital myotonic dystrophy type 1 and offers renewed hope for families affected by this devastating neuromuscular condition.
Source: AMO Pharma press release
